What is HC Wainwright’s Estimate for BLFS Q1 Earnings?

BioLife Solutions, Inc. (NASDAQ:BLFS) – Analysts at HC Wainwright issued their Q1 2027 earnings estimates for BioLife Solutions in a research note issued on Thursday, July 23rd. HC Wainwright analyst Y. Chen anticipates that the medical equipment provider will post earnings per share of $0.03 for the quarter. HC Wainwright has a “Neutral” rating and a $31.00 price objective on the stock. The consensus estimate for BioLife Solutions’ current full-year earnings is $0.02 per share. HC Wainwright also issued estimates for BioLife Solutions’ Q2 2027 earnings at $0.03 EPS, Q3 2027 earnings at $0.05 EPS and Q4 2027 earnings at $0.05 EPS.

A number of other equities analysts have also recently commented on the company. Craig Hallum cut BioLife Solutions from a “buy” rating to a “hold” rating and set a $31.00 price target for the company. in a report on Wednesday. Jefferies Financial Group lowered BioLife Solutions from a “buy” rating to a “hold” rating and upped their price objective for the company from $30.00 to $31.00 in a research note on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a research note on Friday, July 17th. TD Cowen downgraded BioLife Solutions from a “buy” rating to a “hold” rating and reduced their target price for the stock from $33.00 to $31.00 in a research note on Wednesday. Finally, Zacks Research lowered BioLife Solutions from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 12th. One analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $31.43.

BioLife Solutions Stock Performance

Shares of BLFS stock opened at $30.77 on Friday. BioLife Solutions has a 52-week low of $17.86 and a 52-week high of $32.23. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -384.58 and a beta of 1.94. The firm’s 50-day moving average is $26.76 and its 200-day moving average is $23.50.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. The company had revenue of $27.50 million during the quarter, compared to the consensus estimate of $25.66 million. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.81%.

Institutional Investors Weigh In On BioLife Solutions

Several hedge funds have recently bought and sold shares of BLFS. GAMMA Investing LLC boosted its holdings in shares of BioLife Solutions by 36.6% during the second quarter. GAMMA Investing LLC now owns 8,996 shares of the medical equipment provider’s stock worth $254,000 after acquiring an additional 2,410 shares during the period. Bank of America Corp DE grew its position in shares of BioLife Solutions by 73.4% in the first quarter. Bank of America Corp DE now owns 904,103 shares of the medical equipment provider’s stock valued at $17,250,000 after purchasing an additional 382,776 shares during the last quarter. Royal Bank of Canada increased its stake in shares of BioLife Solutions by 8.1% during the first quarter. Royal Bank of Canada now owns 885,298 shares of the medical equipment provider’s stock worth $16,891,000 after purchasing an additional 66,010 shares during the period. Granahan Investment Management LLC increased its stake in shares of BioLife Solutions by 49.7% during the first quarter. Granahan Investment Management LLC now owns 722,057 shares of the medical equipment provider’s stock worth $13,777,000 after purchasing an additional 239,701 shares during the period. Finally, Cannell & Spears LLC lifted its holdings in BioLife Solutions by 3.2% during the 1st quarter. Cannell & Spears LLC now owns 26,261 shares of the medical equipment provider’s stock worth $493,000 after purchasing an additional 825 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at BioLife Solutions

In related news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of BioLife Solutions stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $23.70, for a total transaction of $15,405,000.00. Following the completion of the sale, the insider owned 4,757,165 shares of the company’s stock, valued at approximately $112,744,810.50. The trade was a 12.02% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 1,200,000 shares of company stock worth $28,125,000. Insiders own 2.20% of the company’s stock.

Key BioLife Solutions News

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: Repligen agreed to buy BioLife Solutions for $11.25 in cash and 0.1442 shares of Repligen per BLFS share, a deal that could provide a clear exit value for shareholders. Repligen to buy cell therapy maker BioLife in $1.5 billion deal
• Positive Sentiment: The acquisition gives Repligen access to BioLife’s biopreservation products and expands its cell therapy capabilities, which supports the strategic rationale for the transaction. Repligen to Expand Cell Therapy Capabilities With BioLife Buyout
• Neutral Sentiment: Several law firms announced investigations into whether BioLife shareholders are getting a fair price in the deal, which adds headline risk but does not change the announced terms. BLFS Stock Alert: Halper Sadeh LLC is Investigating Whether BioLife Solutions, Inc. is Obtaining a Fair Price for its Shareholders
• Neutral Sentiment: TD Cowen downgraded BioLife Solutions to Hold, which may temper some near-term enthusiasm after the acquisition news. TD Cowen downgrades BioLife Solutions (BLFS) to a Hold
• Negative Sentiment: Shareholder fairness investigations could create uncertainty, legal noise, and potential delay risk around the transaction closing process. Shareholder Alert: The M&A Class Action Firm Announces An Investigation of BioLife Solutions, Inc.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.